

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

[History of the Urologic Oncology Fellowship](#)

[Bladder Cancer & Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Urothelium

1956	Technique of Urethrectomy
1959	Preoperative Irradiation and Radical Cystectomy
1973	Technique of In-Continuity Urethrectomy during Radical Cystectomy
1974	Outpatient Cystoscopy and Fulguration of Recurrent Superficial Papillary Bladder Tumors
1975	Identification and Characterization of Tumor-Associated Antigens
1979	Diagnostic Value of Urinary Cytology and Flow Cytometry
1979-1984	Intravesical Bacillus Calmette-Guérin (BCG) for Superficial Bladder Tumors and Randomized Trials of BCG, used for FDA Approval
1981	Ureteroscopic Destruction of Upper Tract Tumors

1983	Neoadjuvant MVAC Chemotherapy and Radical Cystectomy
1983-1992	MVAC Chemotherapy Cures Transitional Cell Carcinoma
1983-1995	Bladder-Sparing Strategies for Invasive Bladder Cancer
1989	Prognostic Significance of Lewis Blood Group Antigen
1989-1999	G-CSF Effective with M-VAC Chemotherapy Prognostic Factors Identified
1992-1999	Molecular Analysis (Rb, p53, mdm22, p16, p21, INK4A)
1995-1999	ITP Chemotherapy Improves Survival, and Post-Chemotherapy Surgery Found Beneficial
1997	New Staging for Bladder Cancer (Generated by Memorial Sloan Kettering's Urology Service and Department of Pathology) Adopted by AJCC/UICC
2003-2005	Defined Survival Benefit Related to the Quality of the Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy Defined Refractory Carcinoma-In-Situ
2006	Established an Outcomes Nomogram for Bladder Cancer Patients Undergoing Radical Cystectomy
2007-2009	Described the Treatment Paradigm Shift in Management of T1 Bladder Cancer
2008	Established Pathologic Concerns for Prostate-Sparing Radical Cystectomy Helped to Establish Role of Gemcitabine and Cisplatin in the Neoadjuvant Management of Muscle-Invasive Bladder Cancer
2009	Comprehensively Established Morbidity Associated with Radical Cystectomy and Urinary Diversion
2010	Documented Role of Minimally Invasive Surgical Techniques in the Management of Upper Tract Transitional Cell Carcinoma

2012

Established the Genomic Characteristics of Bladder Cancer
That Will Allow for Targeting Therapy More Effectively in
Bladder Cancer Patients
Data Validating Updated TNM Staging of LN for Bladder
Cancer Patients

Prostate Cancer

Year	Contributions in Treatment and Research
1950-1960	Ablative Surgery Adrenalectomy Exenteration for Locoregional Cancers
1970	Whitmore Staging System (AJCC) Technique of Retropubic I-125 Implantation Natural History Defined
1974	Flutamide Polyamine
1993	Prostate-Specific Monoclonal Antibodies (PSMA) Cloning of PSMA Gene Neoadjuvant Hormonal Therapy and Radical Prostatectomy Three-Dimensional Conformal Radiation Therapy with Intensity Modulation
1995	Flutamide Withdrawal Syndrome
1999	Prognostic Nomograms Nerve Grafts with Radical Prostatectomy Quality of Life, Utility Assessment
2004-2006	Surgeon as an Independent Predictor of Outcomes
2007-2010	Describe Surgical Learning Curve for Radical Prostatectomy
2007-2012	Established Indications for Standard vs Limited Pelvic Lymph Node Dissection
2010	Completed First Comprehensive Genomic Analysis of Prostate Cancer Comprising a Wide Spectrum of the Disease across Multiple Platforms

Testis Cancer

Year	Contributions in Treatment and Research
1960	Technique of Retroperitoneal Lymph Node Dissection
1970-2000	Cisplatin Based Combination Chemotherapy

1972-1980

Cisplatin-Based Combination Chemotherapy
VAB-I through VAB-VI Protocols
Hydration for High-Dose Cisplatin Chemotherapy
Salvage Surgery Post-Chemotherapy
Adjuvant Chemotherapy

1979

Surveillance for Stage I Nonseminomatous Germ Cell Testis Tumors

1983

Risk-Adjusted Treatment Strategies
Salvage Chemotherapies

1988

Marker Gene I(12)p

1997

Staging System Incorporating Tumor Markers Defined
Mechanism of TP53 Mutations and Resistance

1998

Management of Teratoma with Secondary Somatic Malignancy

2000

TIP for Second-Line Chemotherapy

2003

Integration of Markers Status in Clinical Decision Making for Patients with Low-Stage Non-Seminomatous Germ Cell Testis Tumors

2007

High-Dose TICE for Salvage Chemotherapy

2007

Implications of Modified Templates in Low-Stage and Advanced Non-Seminomatous Germ Cell Testis Tumors — Bilateral Infrahilar Is the Gold Standard

2009

Nerve-Sparing Retroperitoneal Lymph Node Dissection following Chemotherapy

2010

Impact of Total Number of Lymph Nodes Resected on Clinical Outcome

2021

First CLIA and State Department of Health (NY) Approval for MSK miRNA Assay (MMA)

2022

Full accrual of “TIGER” Trial (High-Dose Chemotherapy vs TIP)

Renal Cancer

Year	Contributions in Treatment and Research
1949	Technique of Radical Nephrectomy
1975	Tumor Vaccine Developed Monoclonal Antibodies
1979	Partial Nephrectomy in Patients with Normal Contralateral Kidney
1997	Histologic and Molecular Genetic Classification
1998	Randomized Trials of Cis-Retinoic Acid ± Interferon
1997-2000	Prognostic Factors and Nomogram
2006	Partial Nephrectomy Prevents Chronic Kidney Disease
2007-2012	Establishment of Clear Cell Renal Carcinoma-Specific ImmunoPET Scan (G250)

Penile and Urethral Cancer

Year	Contributions in Treatment and Research
1956	Technique of Radical Groin Dissection
1983	Extended Radical Excision (Pubectomy, Emasculation)
1994	Described Myocutaneous Flap Coverage following Massive Groin Dissection with Skin Loss
1996	Risk Stratification for Invasive Penile Cancer
2001	Management of Genitourinary Melanoma Described
2006	Sentinel Lymphoscintigraphy Utilized in Penile Carcinoma and Melanoma

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center